Xiaodong Niu1, Tianwei Wang1, Xingwang Zhou1, Yuan Yang1,2, Xiang Wang1,2, Haodongfang Zhang1, Ni Chen3,2, Qiang Yue4,2, Feng Wang5,2, Yuekang Zhang1, Yanhui Liu6,7, Qing Mao8,9. 1. Department of Neurosurgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China. 2. West China Glioma Centre, West China Hospital, Sichuan University, Chengdu, 610041, China. 3. Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China. 4. Department of Radiology, West China Hospital, Sichuan University, Chengdu, 610041, China. 5. Department of Oncology, West China Hospital, Sichuan University, Chengdu, 610041, China. 6. Department of Neurosurgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China. yhliu2001@163.com. 7. West China Glioma Centre, West China Hospital, Sichuan University, Chengdu, 610041, China. yhliu2001@163.com. 8. Department of Neurosurgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, 610041, China. qingmao2000@163.com. 9. West China Glioma Centre, West China Hospital, Sichuan University, Chengdu, 610041, China. qingmao2000@163.com.
Abstract
PURPOSE: Given the rarity in the population with adult thalamic gliomas (ATGs), comprehensive characteristics, treatments and survival outcome are not well characterized. This study was conducted to investigate the comprehensive characteristic and treatment of ATGs and identify the prognostic factors associated with overall survival (OS). METHODS: A retrospective analysis of newly diagnosed ATGs who underwent surgical resection consecutively was conducted. Survival analysis of OS was performed by Kaplan-Meier analysis. Cox proportional hazard model was used to investigate the possible prognostic factors associated with OS. RESULTS: A total of 102 patients with ATG were enrolled in this study. The median age was 41 years (range 18-68 years). There were 56 (54.9%) males. Sixty-two patients (60.8%) had glioblastoma (GBM). Among these patients, 46 patients (45.1%) had GTR/NTR, 50 patients (49.0%) had STR and 6 patients (5.9%) had PR. Postoperatively, 71.6% of these patients received adjuvant therapy. The median OS was 13.6 months (range 1 week-75 months). COX regression analysis revealed that ATG patients with longer duration of symptoms (p = 0.024), better pre-KPS (p = 0.045), maximal resection (p = 0.013), or lower tumor grade (p = 0.002) had longer OS, and these predictors are considered as independent prognostic factors. Survival analysis showed that ATGs with GTR/NTR plus chemoradiotherapy had significant OS advantage compared with other treatment regimens. CONCLUSIONS: This study comprehensively summarized the characteristics, treatments and survival outcomes of ATGs in the largest sample size. Maximal surgical resection can bring survival benefit. Combined-modality therapy regimen of GTR/NTR plus chemoradiotherapy may be better beneficial for OS than other regimens.
PURPOSE: Given the rarity in the population with adult thalamic gliomas (ATGs), comprehensive characteristics, treatments and survival outcome are not well characterized. This study was conducted to investigate the comprehensive characteristic and treatment of ATGs and identify the prognostic factors associated with overall survival (OS). METHODS: A retrospective analysis of newly diagnosed ATGs who underwent surgical resection consecutively was conducted. Survival analysis of OS was performed by Kaplan-Meier analysis. Cox proportional hazard model was used to investigate the possible prognostic factors associated with OS. RESULTS: A total of 102 patients with ATG were enrolled in this study. The median age was 41 years (range 18-68 years). There were 56 (54.9%) males. Sixty-two patients (60.8%) had glioblastoma (GBM). Among these patients, 46 patients (45.1%) had GTR/NTR, 50 patients (49.0%) had STR and 6 patients (5.9%) had PR. Postoperatively, 71.6% of these patients received adjuvant therapy. The median OS was 13.6 months (range 1 week-75 months). COX regression analysis revealed that ATG patients with longer duration of symptoms (p = 0.024), better pre-KPS (p = 0.045), maximal resection (p = 0.013), or lower tumor grade (p = 0.002) had longer OS, and these predictors are considered as independent prognostic factors. Survival analysis showed that ATGs with GTR/NTR plus chemoradiotherapy had significant OS advantage compared with other treatment regimens. CONCLUSIONS: This study comprehensively summarized the characteristics, treatments and survival outcomes of ATGs in the largest sample size. Maximal surgical resection can bring survival benefit. Combined-modality therapy regimen of GTR/NTR plus chemoradiotherapy may be better beneficial for OS than other regimens.
Authors: David A Solomon; Matthew D Wood; Tarik Tihan; Andrew W Bollen; Nalin Gupta; Joanna J J Phillips; Arie Perry Journal: Brain Pathol Date: 2015-12-14 Impact factor: 6.508
Authors: Matthew J McGirt; Graeme F Woodworth; Alex L Coon; James M Frazier; Eric Amundson; Ira Garonzik; Alessandro Olivi; Jon D Weingart Journal: J Neurosurg Date: 2005-05 Impact factor: 5.115
Authors: Paul Steinbok; Chittur Viswanathan Gopalakrishnan; Alexander R Hengel; Aleksander M Vitali; Ken Poskitt; Cynthia Hawkins; James Drake; Maria Lamberti-Pasculli; Olufemi Ajani; Walter Hader; Vivek Mehta; P Daniel McNeely; Patrick J McDonald; Adrianna Ranger; Michael Vassilyadi; Jeff Atkinson; Scott Ryall; David D Eisenstat; Juliette Hukin Journal: Childs Nerv Syst Date: 2015-11-23 Impact factor: 1.475
Authors: David Castel; Cathy Philippe; Raphaël Calmon; Ludivine Le Dret; Nathalène Truffaux; Nathalie Boddaert; Mélanie Pagès; Kathryn R Taylor; Patrick Saulnier; Ludovic Lacroix; Alan Mackay; Chris Jones; Christian Sainte-Rose; Thomas Blauwblomme; Felipe Andreiuolo; Stephanie Puget; Jacques Grill; Pascale Varlet; Marie-Anne Debily Journal: Acta Neuropathol Date: 2015-09-23 Impact factor: 17.088
Authors: David Castel; Cathy Philippe; Thomas Kergrohen; Martin Sill; Jane Merlevede; Emilie Barret; Stéphanie Puget; Christian Sainte-Rose; Christof M Kramm; Chris Jones; Pascale Varlet; Stefan M Pfister; Jacques Grill; David T W Jones; Marie-Anne Debily Journal: Acta Neuropathol Commun Date: 2018-11-05 Impact factor: 7.801
Authors: Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Hong In Yoon; Chan Woo Wee; Young Zoon Kim; Youngbeom Seo; Jung Ho Im; Yun Sik Dho; Kyung Hwan Kim; Je Beom Hong; Jae Sung Park; Seo Hee Choi; Min Sung Kim; Jangsup Moon; Kihwan Hwang; Ji Eun Park; Jin Mo Cho; Wan Soo Yoon; Se Hoon Kim; Young Il Kim; Ho Sung Kim; Kyoung Su Sung; Jin Ho Song; Min Ho Lee; Myung Hoon Han; Se Hoon Lee; Jong Hee Chang; Do Hoon Lim Journal: Brain Tumor Res Treat Date: 2021-04